for no, mild, moderate and severe disability, respectively. We found substantially lower scores in the health dimensions of independent living, pain, coping, relationships, and self-worth, when compared to Australian norms. Conclusions: For the first time in Australia, we have assessed the HRQoL of Australians with POMS using a detailed preferentially sensitive MAUI. The impact of POMS on health and wellbeing is significant and multifaceted, and increasing disability associated with POMS negatively impacts HRQoL. Effective pain management and support to maintain independent living, relationships, and self-worth can substantially improve the HRQoL of people with POMS.

the costs and effects of treatment with IDegAsp twice daily versus BIAsp 30 twice daily over a 2-year period, from the perspective of Chinese healthcare payers. The clinical data required for the model were obtained from a phase III treat-to-target clinical trial in China (NCT02762578), including insulin dosing, hypoglycemia rates, and reduced body mass index (BMI). Costs including treatment cost and hypoglycemic cost and event-related disutility data were derived from published sources. The insulin prices were the averaged drug provincial biding prices until December 2019 in china. One-way and probabilistic sensitivity analyses were performed. No discounting was applied for such a short time horizon. Results: Compared with BIAsp 30, treatment with IDegAsp was associated with an improvement of 0.0252 (1.5388 vs. 1.5137) quality-adjusted life years (QALYs) over a 2-year time horizon, driven by lower rates of hypoglycemic events, and less additional self-measured blood glucose (SMBG) test for hypoglycemic events. IDegAsp saved 289 CNY for total cost than BIAsp 30 (38,803 vs. 39,092). Cost savings were primarily driven by lower hypoglycemic cost (8,409 CNY, 6,738 vs. 15,147), which offset the higher insulin costs (8,120 CNY, 20,816 vs. 12,696) relative to BIAsp 30. Results were robust across a range of sensitivity analyses. Conclusions: This short-term cost-effectiveness model showed that, compared with BIAsp 30, IDegAsp resulted in a gain of QALYs and savings in costs, and was a dominant treatment option for people with T2DM in China.

Objectives: Gestational diabetes mellitus (GDM) results in serious maternal and neonatal adverse outcomes, including increased risk of miscarriage, macrosomia, complications if glucose levels are not well controlled. In most individuals, they have difficulty in adhering to self-management programs. Telemedicine or technology use is thought to be able to enhance self-management. This review aims to examine the impact of telemedicine in supporting pregnant women with gestational diabetes. Methods: Four databases were systematically searched from database inception to December 31, 2019 for randomised controlled trials that examined telemedicine use in gestational diabetes mellitus. Two independent reviewers assessed for eligibility and risk of bias, with any conflicts resolved by a third reviewer. Random effects-meta analysis was performed. Results: A total of 14 randomised controlled trials which recruited 1,331 pregnant women with GDM were included. Telemedicine were used to monitor and track participants SMBG results and provide education as well as support. Pooled analyses found that women randomised to telemedicine experienced a smaller weight gain (mean difference -1.68 kg [95% CI: -2.91 to -0.46]). However, the effects of telemedicine on other maternal outcomes, such as fasting plasma glucose, HbA1c and need for medication use were equivocal. No significant adverse effects were reported in all studies. Conclusions: The use of telemedicine appears to offer limited additional benefits in women with GDM. Further larger randomised controlled studies are needed to delineate the benefits of telemedicine before these can be recommended for GDM care.

Rapid high-performance liquid chromatographic methods with evaporative light scattering detection (HPLC-ELSD) and electrospray ionization multistage mass spectrometry (HPLC-ESI-MS n ) have been established and validated for simultaneous qualitative and quantitative analysis of eight steroidal saponins in ten batches of Gongxuening capsule (GXN), a widely commercially available traditional Chinese preparation. The optimum chromatographic conditions entailed use of a Kromasil C 18 column with acetonitrile-water (30:70 to 62:38, v/v) as mobile phase at a flow rate of 1.0 mL min −1 . The drift tube temperature of the ELSD was 102°C and the nebulizing gas flow rate was 2.8 L min −1 . Separation was successfully achieved within 25 min. LC-ESI-MS n was used for unequivocal identification of the constituents of the samples by comparison with reference compounds. The assay was fully validated for precision, repeatability, accuracy, and stability, then successfully applied to quantification of the eight compounds in samples. The method could be effective for evaluation of the clinical safety and efficacy of GXN.

incorporation into educational and learning spaces. The program offers a chronogram of activities to be carried out in 12 months. The patient will attend educational, recreational and educational activities, which offer entertainment immersed in a learning environment. Second Level: Patient's College This level will include educational sessions with the medical team where rheumatologists, nurses, administrative staff among others. It will explain in detail disease activity, nutrition, and adherence among others. In this level patients will be assessed. If they approve the exam and desire to continue, they will be promoted to the next level Third Level: Expert Patient This last level focuses on specialization and updating in each area reviewed in College, additionally we will train the patients so that they can educate and teach other patients with rheumatoid arthritis. We plan to implement our program in 2019 in order to evaluate its impact in terms of attendance, disease activity, life quality as well as patients' experience attending each level of our University.